Dr. Van Hove is interested in the development of new treatment for inherited metabolic diseases.
Dr. Van Hove has an interest in neurometabolic diseases that causes seizures, in particular in non-ketotic hyperglycinemia. Dr. Van Hove studies the genetic basis, the clinical spectrum, the prediction of outcome including the relation between genotype and phenotype, the pathogenesis in animal models and human patients and the development of new treatments for this condition. Dr. Van Hove is also interested in pyridoxine dependent epilepsy and related metabolic causes of seizures.
Dr. Van Hove studies energy disorders including mitochondrial respiratory chain diseases and fatty acid oxidation disorders. He is particularly interested in the development of diagnostic assays and in new treatments for these conditions. This has resulted in the use of D,L-3-hydroxybutyrate in severe fatty acid oxidation disorders such as multiple acyl-CoA dehydrogenase deficiency.
Dr. Van Hove directs the mitochondrial core enzyme laboratory for the Childhood Liver Disease Research and Education Network.